9-valent HPV Vaccine in Postpartum Women

Status Not yet recruiting

Clinical Trial Summary

This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.

Clinical Trial Description

Women age 16-45 who are pregnant or who have just delivered will be eligible to participate in a study involving the 9-valent HPV vaccine. For clarification, women who are pregnant are eligible to sign consent, but the first vaccine will not occur until after delivery. Vaccine # 1 must occur within seven days of delivery.

The main objective of the study is to determine the immunogenicity of the vaccine in postpartum women. The immunogenicity results will be compared to that of non-postpartum women of the same age, 16-45.

Women will participate for approximately 12 months and will complete a total of 4 visits during that time frame. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04311528
Study type	Interventional
Source	Augusta University
Contact	Angela Goebel, BS
Phone	706-721-8944
Email	agoebel@augusta.edu
Status	Not yet recruiting
Phase	Phase 4
Start date	April 1, 2020
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05329961` - Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study	Early Phase 1
Completed	`NCT05862844` - Promise Women Project	N/A
Active, not recruiting	`NCT04199078` - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.	N/A
Recruiting	`NCT05566106` - Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Not yet recruiting	`NCT06229353` - Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Completed	`NCT01757392` - Candin Safety & Efficacy Study for the Treatment of Warts	Phase 2
Active, not recruiting	`NCT04716127` - A Proximity-incentive Strategy for Cervical Cancer Screening	N/A
Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
Recruiting	`NCT05835947` - Anal Cancer Risk In Women
Not yet recruiting	`NCT03947775` - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL	Phase 2
Terminated	`NCT03404310` - Zinc Sulfate for Human Papillomavirus (HPV)	N/A
Recruiting	`NCT03302858` - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Phase 2
Completed	`NCT03082950` - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting	`NCT04950101` - Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis	N/A
Recruiting	`NCT05146895` - A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts	N/A
Completed	`NCT04002154` - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV	N/A
Recruiting	`NCT04232917` - Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.	Phase 4
Active, not recruiting	`NCT03729518` - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck	N/A
Recruiting	`NCT05640700` - Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Recruiting	`NCT05362669` - SMS Messaging for Invitation in the Cervical Cancer Screening Programme	N/A